RedHill Biopharma Ltd. plans to change its American Depositary Shares (ADS) ratio from 1:400 to 1:10,000, effective around August 20, 2024, which acts like a 1-for-25 reverse split. This change aims to help the company comply with Nasdaq's minimum bid price requirement following a notification received on March 14, 2024.